Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease
开发用于治疗小儿先天性心脏病的仿生无支架肺心瓣膜
基本信息
- 批准号:10696291
- 负责人:
- 金额:$ 55.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAnimal ModelAnticoagulantsAortaAutologousBiocompatible MaterialsBiomechanicsBiomimetic MaterialsBiomimeticsBioprosthesis deviceBirthBlood flowCardiacCardiac Surgery proceduresCellsChildChildhoodChronicClinicalCoagulation ProcessCollaborationsComplexCongenital AbnormalityCouplingDefectDepositionDevelopmentDevicesEchocardiographyEconomic BurdenEngineeringEpitopesEvaluationFailureFreedomGrowthHealthcare SystemsHeartHeart Valve ProsthesisHeart ValvesHistologicHospital CostsHospitalizationImplantIn VitroInfectionInfiltrationInterventionLegal patentLifeLungMarketingMechanicsMethodsNewborn InfantOperative Surgical ProceduresPatientsPhasePhysiologicalPolymersPolyurethanesProceduresProcessPropertyProsthesisProtocols documentationPulmonary valve structureQualifyingQuality of lifeRepeat SurgeryResistanceRestRiskSmall Business Technology Transfer ResearchSpatial DistributionStructural defectStructureSurgeonSurgical ValvesTechnologyTestingThickThromboembolismThrombosisThrombusTissuesUniversitiesbiomechanical testbioprocesscalcificationcardiac tissue engineeringcongenital heart disordercostdesignheart valve replacementhemodynamicshigh riskhuman tissueimplantationimprovedin vitro testingin vivoin vivo evaluationmanufactureneglectoperationpediatric patientsprototypepulmonary valve replacementregeneration potentialscaffoldsheep modelsuccesstherapy developmentthrombogenesistissue regenerationvalve replacement
项目摘要
PROJECT SUMMARY
Congenital heart disease (CHD) is caused by defects in the heart structure that occur at birth and affect blood
flow through the heart and the rest of the body. CHD affects around 10 out of 1,000 live-born children, 25% of
which will need an intervention or surgery within their first year of life. Circa 1 million children and 1.4 million
adults live with CHD in the US, and over 182,000 heart valve replacements are performed every year. Currently,
available heart valve prostheses do not perform as native cardiac tissue and have several limitations related to
their durability and ability to support tissue regeneration. In addition, they have been associated with
complications such as clots, increased risk of thrombosis and thromboembolism, calcification, and infection.
Replacement of bioprosthetic valves often requires complex and high-risk operations and poses an economic
burden of $1.7B in the US per year to the healthcare system.
Neoolife aims to overcome these major drawbacks in CHD therapy by developing tissue engineered heart
valves (TEHVs) that are fabricated using scaffolds that mimic human tissue. Through endogenous tissue growth,
Neoolife’s biomimetic pulmonary heart valves are extensively augmented or eventually replaced, leaving
autologous and functional leaflets that grow with the CHD pediatric patient that are durable and non-
thrombogenic. These biomimetic valves do not require life-long blood thinner treatments and are resistant to
calcification and infection. In this STTR Phase I project, Neoolife will modify its proprietary Double Component
Deposition (DCD) technology to obtain a more homogeneous biomimetic scaffold deposition. Biomimetic
pulmonary heart valve prototypes (n=10) will be fabricated using a new multiple stage processing setup. The
prototypes will be tested in vitro for their mechanical and functional properties and assessed in vivo (n=5, 180
days) to evaluate polymer degradation, cellularization, biomechanics, and valve function.
In Phase II, further in vitro and in vivo studies will be performed to provide sufficient technical information to
demonstrate that Neoolife developed pulmonary heart valve qualifies for obtaining a Humanitarian Device
Exemption (HDE) designation for the treatment of pediatric CHD.
项目摘要
先天性心脏病(CHD)是由出生时发生的心脏结构缺陷引起的,
流经心脏和身体其他部位CHD影响大约1,000个活产婴儿中的10个,
在出生后的第一年内需要进行干预或手术。大约100万儿童和140万
在美国,成年人患有CHD,每年进行超过182,000例心脏瓣膜置换术。目前,
可用的心脏瓣膜假体不能作为天然心脏组织工作
它们的耐久性和支持组织再生的能力。此外,他们还与
并发症,如凝块、血栓形成和血栓栓塞的风险增加、钙化和感染。
生物假体瓣膜的置换通常需要复杂且高风险的手术,并且对患者造成经济损失。
美国每年为医疗保健系统带来17亿美元的负担。
Neoolife旨在通过开发组织工程心脏来克服CHD治疗中的这些主要缺点
瓣膜(TEHV)是使用模拟人体组织的支架制造的。通过内源性组织生长,
Neoolife的仿生肺动脉心脏瓣膜被广泛增强或最终被替换,
与CHD儿科患者一起生长的自体和功能性瓣叶,耐用且非
血栓形成的这些仿生瓣膜不需要终生的血液稀释剂治疗,
钙化和感染。在这个STTR第一阶段项目中,Neoolife将修改其专有的双组分
沉积(DCD)技术,以获得更均匀的仿生支架沉积。仿生
将使用新的多阶段处理装置制造肺动脉心脏瓣膜原型(n=10)。的
将在体外测试原型的机械和功能特性,并在体内进行评估(n=5,180
天)以评价聚合物降解、细胞化、生物力学和瓣膜功能。
在II期,将进行进一步的体外和体内研究,以提供足够的技术信息,
证明Neoolife开发的肺动脉心脏瓣膜有资格获得人道主义器械
治疗儿科CHD的豁免(HDE)指定。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Garrett N Coyan其他文献
Garrett N Coyan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 55.38万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 55.38万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 55.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 55.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 55.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)